Summary of indirect comparisons to evaluate efficacy of baricitinib with targeted synthetic and biologic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis

被引：0
|
作者：
Emery, P. [1 ]
Dudler , J. [2 ]
Smolen, J. [3 ]
Zerbini, C. [4 ]
Burmester, G. [5 ]
Fautrel, B. [6 ]
van de Laar, M. [7 ]
Fleischmann, R. [8 ]
Fakhouri, W. [9 ]
De Leonardis, F. [9 ]
Zhu, B. [9 ]
Kadziola, Z. [9 ]
De La Torre, I [9 ]
Perrier, C. [9 ]
Taylor, P. [10 ]
机构：
[1] Leeds MSK Biomed Chapel Allerton Hosp, Leeds, W Yorkshire, England
[2] HFR Fribourg Hop Cantonal, Fribourg, Switzerland
[3] Med Univ Vienna, Vienna, Austria
[4] Ctr Paulista Invest Sao Paulo Clin, Sao Paulo, Brazil
[5] Charite Univ Med Berlin, Dept Rheumatol & Clin Immunol, Berlin, Germany
[6] Pierre & Marie Curie, Paris, France
[7] Arthritis Ctr Twente, Enschede, Netherlands
[8] Univ Texas SouthWestern Med Ctr, Dallas, TX USA
[9] Eli Lilly & Co, Indianapolis, IN USA
[10] Univ Oxford, Botnar Res, Headington, England
来源：
SWISS MEDICAL WEEKLY | 2019年
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P 6
引用
收藏
页码：7S / 8S
页数：2
相关论文
共 50 条
  • [31] Risk factors for bone loss in patients with rheumatoid arthritis treated with biologic disease-modifying anti-rheumatic drugs
    Tawaratsumida H.
    Setoguchi T.
    Arishima Y.
    Ohtsubo H.
    Akimoto M.
    Ishidou Y.
    Nagano S.
    Taketomi E.
    Sunahara N.
    Komiya S.
    BMC Research Notes, 10 (1)
  • [32] Assessment of adherence to disease-modifying anti-rheumatic drugs in rheumatoid arthritis
    Clélia Monchablon
    Henri Gondé
    Sophie Pouplin
    Rémi Varin
    Olivier Vittecoq
    Thierry Lequerré
    Clinical Rheumatology, 2020, 39 : 207 - 216
  • [33] Effect of biologic disease-modifying anti-rheumatic drugs for patients with rheumatoid arthritis who hope to become mothers
    Hiromi Shimada
    Tomohiro Kameda
    Kenji Kanenishi
    Nobuyuki Miyatake
    Shusaku Nakashima
    Risa Wakiya
    Mikiya Kato
    Taichi Miyagi
    Mai Mahmoud Fahmy Mansour
    Toshiyuki Hata
    Norimitsu Kadowaki
    Hiroaki Dobashi
    Clinical Rheumatology, 2019, 38 : 1453 - 1458
  • [34] Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study
    Joensuu, Jaana T.
    Aaltonen, Kalle J.
    Aronen, Pasi
    Sokka, Tuulikki
    Puolakka, Kari
    Tuompo, Riitta
    Korpela, Markku
    Vasala, Mikko
    Ilva, Kirsti
    Nordstrom, Dan
    Blom, Marja
    RHEUMATOLOGY, 2016, 55 (10) : 1803 - 1811
  • [35] Use of disease-modifying anti-rheumatic drugs and cardiovascular events in patients with rheumatoid arthritis
    Kaminski, Matthew
    Shishehbor, Mehdi H.
    Gutierrez, Antonio
    Amini, Mohammad R.
    Coats, Walter
    Moghbelli, Meisam
    Askari, Arman T.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (10) : A370 - A370
  • [36] EFFICACY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS STRATIFIED BY NUMBER OF PRIOR BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
    Mease, P. J.
    Lertratanakul, A.
    Strober, B.
    Tsuji, S.
    Richette, P.
    Lovan, C.
    Feng, D.
    Anderson, J.
    Van den Bosch, F.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 788 - 789
  • [37] Disease-modifying anti-rheumatic drugs improve the cardiovascular profile in patients with rheumatoid arthritis
    Giachi, Andrea
    Cugno, Massimo
    Gualtierotti, Roberta
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [38] Efficacy of Upadacitinib in Patients with Psoriatic Arthritis Stratified by Number of Prior Biologic Disease-modifying Anti-rheumatic Drugs
    Mease, Philip
    Lertratanakul, Apinya
    Strober, Bruce
    Tsuji, Shigeyoshi
    Richette, Pascal
    Lovan, Charlie
    Feng, Dai
    Anderson, Jaclyn K.
    Van den Bosch, Filip
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [39] PREDICTIVE FACTORS FOR SUCCESSFUL BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS DOSE TAPERING IN RHEUMATOID ARTHRITIS
    Loh, Min Yi
    Jones, Claire J.
    Peall, Adrian
    Trickey, Jeanette
    RHEUMATOLOGY, 2023, 62
  • [40] IMPACT OF BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN LIPID PROFILE OF PSORIATIC ARTHRITIS PATIENTS
    Guajardo-Aldaco, Andrea L.
    Galarza-Delgado, Dionicio A.
    Azpiri-Lopez, Jose R.
    Colunga-Pedraza, Iris J.
    Cardenas-de la Garza, Jesus A.
    Arvizu-Rivera, Rosa I.
    Elizondo-Benitez, Maria F.
    Gonzalez-Gonzalez, Valeria
    ACTA DERMATO-VENEREOLOGICA, 2024, 104
12345